Pilot-Scale Enzymatic Conversion of Low Stability, High Free Fatty, Squid Oil to an Oxidatively Stable Astaxanthin-Rich Acylglyceride Oil Suitable for Nutritional Applications
Marine Drugs · 2025
DOI: 10.3390/md23010021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Marine Drugs, 2025. Verfasst von Asavari Joshi und 3 weiteren Autor:innen. Beteiligte Einrichtung: ARC Industrial Transformation Training Centre for Green Chemistry in Manufacturing, Deakin University, Waurn Ponds, Geelong, VIC 3216, Australia. Hauptthemen laut MEDLINE: Lipase, Decapodiformes, Fatty Acids, Nonesterified, Oils. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Australian Research Council, Australian Research Council Industrial Transformation Training Centre.
Abstract (Originalsprache)
Squid viscera, a byproduct of squid processing, contains oil rich in omega-3 fatty acids (up to 10% by mass) and the antioxidant astaxanthin. However, its high free fatty acid (FFA) content compromises stability. To address this, pilot-scale (200 L) enzymatic re-esterification of squid oil using immobilized lipase (Lipozyme RMIM) was demonstrated, resulting in high acylglyceride yields. The processed oil was analyzed for oxidation kinetics and thermodynamics using Rancimat, fatty acid composition using GC, omega-3 fatty acid positional distribution in the acylglyceride product using 13C NMR, and astaxanthin content. Lipase treatment reduced FFA levels from 44% to 4% and increased acylglycerides to 93% in squid oil. This reduction in FFA was accompanied by significantly increased stability (0.06 to 18.9 h by Rancimat). The treated oil showed no loss in astaxanthin (194.1 µg/g) or omega-3 fatty acids, including docosahexaenoic acid (DHA). DHA remaining predominantly at sn-2 indicated that the naturally occurring positional distribution of this omega-3 FFA was retained in the product. Lipase treatment significantly enhanced oxidative stability, evidenced by improved thermodynamic parameters (Ea 94.15 kJ/mol, ΔH 91.09 kJ/mol, ΔS −12.6 J/mol K) and extended shelf life (IP25 74.42 days) compared to starting squid oil and commercial fish/squid oils lacking astaxanthin. Thus, lipase treatment offers an effective strategy for reducing FFA levels and producing oxidatively stable, astaxanthin-rich acylglyceride squid oil with DHA retained at the nutritionally favored sn-2 position.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- ARC Industrial Transformation Training Centre for Green Chemistry in Manufacturing, Deakin University, Waurn Ponds, Geelong, VIC 3216, Australia.
- Centre for Sustainable Bioproducts, Deakin University, Waurn Ponds, Geelong, VIC 3216, Australia.
- Australian Omega Oils Pty Ltd., North Geelong, Geelong, VIC, 3215, Australia.
- Distinguished Visiting Research Fellow, College of Engineering, Abu Dhabi University, Zayed City 59911, Abu Dhabi, United Arab Emirates.
ORCID-Profile: Asavari Joshi, Colin J Barrow
Förderung
- Australian Research Council
- Australian Research Council Industrial Transformation Training Centre
Zitieren
APA
Joshi, A., Holland, B., Sachar, M., & Barrow, C. J. (2025). Pilot-Scale Enzymatic Conversion of Low Stability, High Free Fatty, Squid Oil to an Oxidatively Stable Astaxanthin-Rich Acylglyceride Oil Suitable for Nutritional Applications. Marine Drugs. https://doi.org/10.3390/md23010021
Vancouver
Joshi A, Holland B, Sachar M, Barrow CJ. Pilot-Scale Enzymatic Conversion of Low Stability, High Free Fatty, Squid Oil to an Oxidatively Stable Astaxanthin-Rich Acylglyceride Oil Suitable for Nutritional Applications. Marine Drugs. 2025. doi:10.3390/md23010021
BibTeX
@article{Joshi2025,
author = {Joshi, Asavari and Holland, Brendan and Sachar, Moninder and Barrow, Colin J},
title = {Pilot-Scale Enzymatic Conversion of Low Stability, High Free Fatty, Squid Oil to an Oxidatively Stable Astaxanthin-Rich Acylglyceride Oil Suitable for Nutritional Applications},
journal = {Marine Drugs},
year = {2025},
doi = {10.3390/md23010021}
}
EUVIMED